RESUMO
The requirement for robust analytical methods to characterize adeno-associated virus (AAV) vectors is immediate, as the field advances more AAV gene therapies into the clinic and onto commercialization. AAV capsid proteins (VPs) are critical for viral infectivity and vector potency. Thus, complete characterization of the constituent viral capsid proteins of AAV vectors, including their sequences and post-translational modifications (PTMs), is highly recommended to ensure AAV product quality and consistency. Typically, SDS-PAGE analysis followed by in-gel enzymatic digestion and liquid chromatography/tandem mass spectrometry (LC/MS/MS) is used for the characterization of viral capsid proteins. However, due to the limited recovery of digested peptides from the gel, determination of N-terminal sequences of VPs has not been reported to date. In this study, a direct liquid chromatography/mass spectrometry (LC/MS) intact protein analysis was developed to characterize viral capsid proteins in a variety of AAV serotypes. Both N- and C-terminal sequences of six AAV serotypes have been identified based on accurate mass measurement. This method can be used to confirm the identity of AAV serotype and monitor potential capsid protein heterogeneity. Complete sequence confirmation of AAV2 VPs was achieved through LC/MS/MS analysis of peptides generated using multiple enzymatic digestions. LC/MS/MS analysis confirmed the sequences for both N- and C-termini of capsid VPs and revealed acetylation on the N-termini of VP1 and VP3, consistent with LC/MS intact protein analysis.
Assuntos
Proteínas do Capsídeo/análise , Cromatografia Líquida de Alta Pressão , Dependovirus/genética , Vetores Genéticos/metabolismo , Espectrometria de Massas em Tandem , Sequência de Aminoácidos , Proteínas do Capsídeo/genética , Proteínas do Capsídeo/metabolismo , Eletroforese em Gel de Poliacrilamida , Vetores Genéticos/genética , Células HeLa , Humanos , Mapeamento de Peptídeos , Peptídeos/análise , Proteínas Recombinantes/análise , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/isolamento & purificação , Alinhamento de Sequência , SorogrupoRESUMO
Niemann-Pick disease type B (NPD-B) is caused by a partial deficiency of acid sphingomyelinase activity and results in the accumulation of lysosomal sphingomyelin (SPM) predominantly in macrophages. Notably, SPM is not significantly elevated in the plasma, whole blood, or urine of NPD-B patients. Here, we show that the de-acylated form of sphingomyelin, lyso-SPM, is elevated approximately 5-fold in dried blood spots (DBS) from NPD-B patients and has no overlap with normal controls, making it a potentially useful biomarker.
Assuntos
Células Sanguíneas/química , Doença de Niemann-Pick Tipo B/sangue , Fosforilcolina/análogos & derivados , Esfingomielina Fosfodiesterase/deficiência , Esfingosina/análogos & derivados , Estudos de Casos e Controles , Teste em Amostras de Sangue Seco , Humanos , Lisossomos/metabolismo , Lisossomos/patologia , Macrófagos/metabolismo , Macrófagos/patologia , Doença de Niemann-Pick Tipo B/diagnóstico , Doença de Niemann-Pick Tipo B/patologia , Fosforilcolina/isolamento & purificação , Esfingosina/isolamento & purificaçãoRESUMO
BACKGROUND: New York State has screened over 1.2 million newborns for Krabbe disease, and we identified 4 newborns with infantile Krabbe disease. In addition, 6 other newborns were identified with very low galactosylcerebrosidase (GALC) activity. Because these patients remain asymptomatic, we investigated whether psychosine levels could be a useful marker for disease. METHODS: HPLC-MS/MS methodology was used to determine the psychosine concentrations in dried blood spots (DBS) collected from the following cohorts: known Krabbe patients, screened babies that were determined to have infantile Krabbe disease, asymptomatic infants with low GALC activity, and normal controls. RESULTS: The psychosine concentrations from the known Krabbe patients ranged from 7 to 50 ng/ml. Newborns identified by screening who were confirmed with infantile Krabbe disease ranged from 23 to 73 ng/ml. Asymptomatic individuals with low GALC activity had concentrations ranging from 1.7 to 5.7 ng/ml. Concentrations in newborns with normal GALC activity were all <3 ng/ml. CONCLUSIONS: The psychosine concentrations in DBS from confirmed infantile patients are at least four times higher than the asymptomatic newborns and nearly an order of magnitude greater than normal newborns. Further studies are needed to determine if psychosine can be used as a predictor of disease status/progression in screen positive newborns.
Assuntos
Teste em Amostras de Sangue Seco , Leucodistrofia de Células Globoides/sangue , Triagem Neonatal , Psicosina/sangue , Adolescente , Criança , Pré-Escolar , Suscetibilidade a Doenças , Humanos , Lactente , Recém-Nascido , Fatores de RiscoRESUMO
BACKGROUND: We sought to modify a previously published tandem mass spectrometry method of screening for 5 lysosomal storage disorders (LSDs) in order to make it better suited for high-throughput newborn screening. METHODS: Two 3-mm dried blood spot (DBS) punches were incubated, each with a different assay solution. The quadruplex solution was used for screening for Gaucher, Pompe, Krabbe and Fabry diseases, while a separate solution was used for Niemann-Pick A/B disease. RESULTS: The mean activities of acid-ß-glucocerebrosidase (ABG), acid sphingomyelinase (ASM), acid glucosidase (GAA), galactocerebroside-ß-galactosidase (GALC) and acid-galactosidase A (GLA) were measured on 5055 unidentified newborns. The mean activities (compared with their disease controls) were, 15.1 (0.35), 22.2 (1.34), 16.8 (0.51), 3.61 (0.23), and 20.7 (1.43) (µmol/L/h), respectively. The number of specimens that fell below our retest level cutoff of <20% daily mean activity (DMA) for each analyte is: ABG (6), ASM (0), GAA (5), GALC (17), and GLA (2). CONCLUSIONS: This method provides a simplified and reliable assay for screening for five LSDs with clear distinction between activities from normal and disease samples. Advantages of this new method include significant decreases in processing time and the number of required assay solutions and overall decreased complexity.
Assuntos
Doenças por Armazenamento dos Lisossomos/diagnóstico , Triagem Neonatal/métodos , Espectrometria de Massas em Tandem/métodos , Teste em Amostras de Sangue Seco , Doença de Fabry/diagnóstico , Galactosilceramidase/sangue , Doença de Gaucher/diagnóstico , Glucosilceramidase/sangue , Doença de Depósito de Glicogênio Tipo II/diagnóstico , Humanos , Recém-Nascido , Leucodistrofia de Células Globoides/diagnóstico , Doenças por Armazenamento dos Lisossomos/sangue , Doenças de Niemann-Pick/diagnóstico , Controle de Qualidade , Esfingomielina Fosfodiesterase/sangue , alfa-Glucosidases/sangueRESUMO
BACKGROUND: Fluorometric and tandem mass spectrometry assays can be used to measure lysosomal enzyme activities in dried blood spots (DBS). The effect of DBS preparation, storage and shipping was evaluated on the activities of acid α-glucosidase, acid α-galactosidase, acid ß-glucocerebrosidase, acid sphingomyelinase, and galactocerebrosidase. METHODS: Whole blood from normal donors was used to prepare DBS following Clinical and Laboratory Standards Institute guidelines and by several deviations. Some DBS were subjected to various treatments, storage and shipping conditions. The activity of 5 lysosomal enzymes (GAA, GLA, GBA, ASM, and GALC) was measured using tandem mass spectrometric and fluorometric (GAA only) assays with 2 distinct and commonly used synthetic substrates. RESULTS: Enzyme activities were strongly affected by the way DBS were prepared and stored. Exposure of DBS to elevated heat and humidity can destroy enzyme functions rapidly. DBS prepared from poorly mixed blood caused significant variation on enzyme activities. EDTA, but not heparin, as an anti-coagulant gave more precise results. CONCLUSIONS: The study confirmed the importance of proper and consistent DBS preparation and storage when screening for deficiencies of lysosomal enzymes.
Assuntos
Métodos Analíticos de Preparação de Amostras/métodos , Coleta de Amostras Sanguíneas/métodos , Ensaios Enzimáticos/métodos , Hidrolases/sangue , Hidrolases/metabolismo , Lisossomos/enzimologia , Adulto , Métodos Analíticos de Preparação de Amostras/instrumentação , Coagulação Sanguínea/efeitos dos fármacos , Coleta de Amostras Sanguíneas/instrumentação , Volume Sanguíneo , Ácido Edético/farmacologia , Ensaios Enzimáticos/instrumentação , Filtração , Fluorometria , Heparina/farmacologia , Humanos , Papel , Espectrometria de Massas em Tandem , TemperaturaRESUMO
BACKGROUND: Gaucher disease (GD) is due to deficiency of acid-ß-glucosidase (ABG) and comprises a clinical spectrum with variable age of onset and severity. We evaluated a tandem mass spectrometry (MS/MS) method to measure ABG activity for high through-put screening. METHODS: ABG activity was measured in 3.2 mm punches from dry blood spots (DBS). Each punch was incubated for 21 h with the substrate D-Glucosyl-ß1-1'-N-dodecanoyl-D-erythro-sphingosine [C12-glucocerebroside (C(36)H(69)NO(8))] and internal standard N-myristoyl-D-erythro-sphingosine [C14-ceramide (C(32)H(63)NO(3))]. The product and internal standard were quantified using MS/MS. RESULTS: ABG activities in anonymized newborn screening samples from NY State were (mean) 22.0 µmol/h/L±(SD) 13.8 µmol/h/L (n=2088, median 19.9 µmol/h/L, 95%CI 22.59-21.41 µmol/h/L). The enzymatic activity in DBS from 10 treatment naïve adult Gaucher patients was less than 4.2 µmol/h/L. ABG activity was stable for 3 months at room temperature a 20% activity reduction was observed. Inter- and intra-run imprecisions were 8% and 13.7%, respectively. The limit of detection was 0.75 µmol/h/L and limit of quantification was 1.25 µmol/h/L. CONCLUSIONS: The measurement of ABG activities in DBS using MS/MS is suitable for high-throughput analysis of at-risk individuals and potentially for newborn screening for GD.
Assuntos
Coleta de Amostras Sanguíneas/métodos , Ensaios Enzimáticos/métodos , Glucosilceramidase/sangue , Glucosilceramidase/metabolismo , Espectrometria de Massas em Tandem/métodos , Adulto , Estudos de Casos e Controles , Estabilidade Enzimática , Doença de Gaucher/sangue , Doença de Gaucher/diagnóstico , Doença de Gaucher/enzimologia , Humanos , Recém-Nascido , Reprodutibilidade dos TestesRESUMO
BACKGROUND: Fabry disease is characterized by accumulation of glycosphingolipids, such as globotriaosylceramide (Gb(3)), in many tissues and body fluids. A novel plasma biomarker, globotriaosylsphingosine (lyso-Gb(3)), is increased in patients with the disease. Until now, lyso-Gb(3) was not detectable in urine, possibly because of the presence of interfering compounds. METHODS: We undertook to: 1) characterize lyso-Gb(3) in urine; 2) develop a method to quantitate urinary lyso-Gb(3) by mass spectrometry; 3) evaluate urinary lyso-Gb(3) as a potential biomarker for Fabry disease; and 4) determine whether lyso-Gb(3) is an inhibitor of α-galactosidase A activity. We analyzed urinary lyso-Gb(3) from 83 Fabry patients and 77 healthy age-matched controls. RESULTS: The intraday and interday bias and precision of the method were <15%. Increases in lyso-Gb(3)/creatinine correlated with the concentrations of Gb(3) (r(2)=0.43), type of mutations (p=0.0006), gender (p<0.0001) and enzyme replacement therapy status (p=0.0012). Urine from healthy controls contained no detectable lyso-Gb(3). Lyso-Gb(3) did not inhibit GLA activity in dried blood spots. Increased urinary excretion of lyso-Gb(3) of Fabry patients correlated well with a number of indicators of disease severity. CONCLUSION: Lyso-Gb(3) is a reliable independent biomarker for clinically important characteristics of Fabry disease.
Assuntos
Doença de Fabry/urina , Glicolipídeos/urina , Esfingolipídeos/urina , Urinálise/métodos , Adolescente , Adulto , Idoso , Biomarcadores/urina , Estudos de Casos e Controles , Criança , Pré-Escolar , Creatina/urina , Doença de Fabry/enzimologia , Doença de Fabry/fisiopatologia , Feminino , Glicolipídeos/farmacologia , Humanos , Rim/fisiopatologia , Masculino , Pessoa de Meia-Idade , Psicosina/análogos & derivados , Psicosina/urina , Padrões de Referência , Reprodutibilidade dos Testes , Fatores Sexuais , Esfingolipídeos/farmacologia , Urinálise/normas , Adulto Jovem , alfa-Galactosidase/antagonistas & inibidoresRESUMO
BACKGROUND: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by the deficiency of alpha-galactosidase A (GLA). We evaluated a tandem mass spectrometry method to measure GLA activity. METHODS: One 3.2mm punch from a dried blood spot sample (DBS) was incubated with substrate and internal standard in the reaction buffer for 22 h. The resulting product was quantified against internal standard using MS/MS. RESULTS: The median GLA activity of male newborn DBS (N=5025) was 9.85 + or - 6.4 micromol/h/l (CI 95% is 9.67-10.02 micromol/h/l); The median GLA activity of female newborns (N=4677) was 10.2 + or - 6.3 micromol/h/l (CI 95% is 10.02-10.38 micromol/h/l). The difference between the two subgroups is within assay analytical variation. The GLA activities in the DBS samples from 9 juvenile and adult males with previously identified FD were below 1.64 micromol/h/l. The GLA activities from 32 juvenile and adult females with confirmed FD were below 4.73 micromol/h/l. In 5 (16%) females GLA activities were above the 0.5th percentile of lower limit of CI 95% at 3.18 micromol/h/l. CONCLUSIONS: The MS/MS method for Fabry disease newborn screening is robust and can be readily multiplexed with other lysosomal disorders such as Pompe, Gaucher, Niemann-Pick, and Krabbe diseases.
Assuntos
Doença de Fabry/diagnóstico , Triagem Neonatal/métodos , Espectrometria de Massas em Tandem/métodos , alfa-Galactosidase/metabolismo , Feminino , Humanos , Recém-Nascido , Masculino , Fatores Sexuais , alfa-Galactosidase/sangueRESUMO
Deficiencies in any of the 50 degradative enzymes found in lysosomes results in the accumulation of undegraded material and subsequently cellular dysfunction. Early identification of deficiencies before irreversible organ and tissue damages occur leads to better clinical outcomes. In the method which follows, lysosomal alpha-glucosidase, alpha-galactosidase, beta-glucocerebrosidase, acid sphingomyelinase, and galactocerebrosidase are extracted from dried blood spots and incubated individually with an enzyme-specific cocktail containing the corresponding substrate and internal standard. Each enzyme cocktail is prepared using commercially available mixture of substrate and internal standard at the predetermined optimized molar ratio. After incubation, the enzymatic reactions are quenched using an ethyl acetate/methanol solution and all five enzyme solutions are combined. The mixtures of the reaction products are prepared using liquid-liquid and solid-phase extractions and quantified simultaneously using selected ion monitoring on LC-MS-MS system.
Assuntos
Ensaios Enzimáticos/métodos , Espectrometria de Massas em Tandem/métodos , Galactosilceramidase/metabolismo , Glucosilceramidase/metabolismo , Humanos , Padrões de Referência , Reprodutibilidade dos Testes , Esfingomielina Fosfodiesterase/metabolismo , alfa-Galactosidase/metabolismo , alfa-Glucosidases/metabolismoRESUMO
OBJECTIVE: The aim of this study was to develop a newborn screening algorithm for Krabbe disease. DESIGN AND METHODS: We measured the galactocerebrosidase activity of 139,074 anonymous newborns, 56 known carriers, and 16 Krabbe patients using a tandem mass spectrometry method. The activities were converted to percentages of daily mean activity (%DMA), and the results from diseased and normal populations were used to establish cutoffs. RESULTS: The absolute activities for the newborns ranged from 0.17 to 355 micromol/L h (N=139,074) and activities for Krabbe-positive controls ranged from 0.08 to 0.48 micromol/L h (N=16, n=91 measurements) while activities for carriers ranged from 0.28 to 2.71 micromol/L h (N=56, n=72 measurements). Cutoffs were set based on results from Krabbe-positive and carrier controls and the newborn population distribution. CONCLUSIONS: The algorithm and cutoffs we propose provided 100% detection of all positive controls with 60/100,000 screen positive results predicted. In the course of this study, one anonymous newborn was predicted to have Krabbe disease based on enzyme activity and subsequent DNA analysis.
Assuntos
Leucodistrofia de Células Globoides/diagnóstico , Triagem Neonatal/métodos , Adolescente , Criança , Pré-Escolar , Humanos , Lactente , Recém-Nascido , Reprodutibilidade dos Testes , Espectrometria de Massas em TandemRESUMO
BACKGROUND: Fabry disease is an X-linked lysosomal storage disorder due to deficiency of alpha galactosidase A (AGAL, EC 3.2.1.22). Despite increasing utilization of dried blood spot (DBS) as samples for AGAL enzyme assays, the effects of blood sample collection techniques on enzyme activity have not been studied. METHODS: DBS samples were prepared by spotting blood collected into an ethylenediaminetetraacetic acid (EDTA) tube and by direct application of blood from a finger prick or a venipuncture syringe. AGAL activity was measured quantitatively by detecting the fluorescence of 4-methylumbelliferone (4-MU) generated using the substrate 4-methylumbelliferyl-alpha-D-glucopyranoside (4-MUGal) in an acidic pH for 20 h. N-acetyl-D-galactosamine (GalNAc) was used to inhibit alpha-galactosidase B (EC 3.2.1.49). RESULTS: We studied 88 previously diagnosed Fabry disease patients and 690 healthy controls. Average AGAL activity in DBS samples prepared using EDTA tubes was higher compared to those spotted directly irrespective of disease status. CONCLUSIONS: The study confirms the need for collection method-specific reference ranges using DBS samples.
Assuntos
Análise Química do Sangue/métodos , Filtração , Papel , Manejo de Espécimes/métodos , alfa-Galactosidase/sangue , alfa-Galactosidase/metabolismo , Adulto , Estudos de Casos e Controles , Relação Dose-Resposta a Droga , Ácido Edético/farmacologia , Doença de Fabry/sangue , Doença de Fabry/enzimologia , Feminino , Humanos , Masculino , Reprodutibilidade dos TestesRESUMO
BACKGROUND: Lysosomal storage disorders (LSDs) comprise more than 40 genetic diseases that result in the accumulation of products that would normally be degraded by lysosomal enzymes. A tandem mass spectrometry (MS/MS)-based method is available for newborn screening for 5 LSDs, and many laboratories are initiating pilot studies to evaluate the incorporation of this method into their screening panels. We developed and evaluated dried blood spot (DBS) QC materials for LSDs and used the MS/MS method to investigate their suitability for LSD QC monitoring. METHODS: We incubated 3.2-mm punches from DBS controls for 20-24 h with assay cocktails containing substrate and internal standard. Using MS/MS, we quantified the resulting product and internal standard. Samples were run in triplicate for 3 consecutive days, and results were reported as product-to-internal standard ratios and enzyme activity units (micromol/L/h). RESULTS: Enzyme activity interday imprecision (CV) for the high, medium, and low series were 3.4%-14.3% for galactocerebroside alpha-galactosidase, 6.8%-24.6% for acid alpha-galactosidase A, 7.36%-22.1% for acid sphingomyelinase, 6.2%-26.2% for acid alpha-glucocerebrosidase, and 7.0%-24.8% for lysosomal acid alpha-glucosidase (n = 9). In addition, DBS stored at -20 degrees and 4 degrees C showed minimal enzyme activity loss over a 187-d period. DBS stored at 37 degrees and 45 degrees C had lower activity values over the 187-day evaluation time. CONCLUSIONS: Suitable QC materials for newborn screening of LSDs were developed for laboratories performing DBS LSD screening. Good material linearity was observed, with goodness-of-fit values of 0.953 and higher. The QC materials may be used by screening laboratories that perform LSD analysis by MS and/or more conventional fluorescence-based screening methods.
Assuntos
Coleta de Amostras Sanguíneas , Glucosidases/sangue , Doenças por Armazenamento dos Lisossomos/sangue , Doenças por Armazenamento dos Lisossomos/diagnóstico , Triagem Neonatal , Esfingomielina Fosfodiesterase/sangue , alfa-Galactosidase/sangue , Humanos , Recém-Nascido , Doenças por Armazenamento dos Lisossomos/enzimologia , Controle de Qualidade , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Espectrometria de Massas em TandemRESUMO
BACKGROUND: Pompe disease, caused by the deficiency of acid alpha-glucosidase (GAA), is a lysosomal storage disorder that manifests itself in its most severe form within the first months of life. Early detection by newborn screening is warranted, since prompt initiation of enzyme replacement therapy may improve morbidity and mortality. We evaluated a tandem mass spectrometry (MS/MS) method to measure GAA activity for newborn screening for Pompe disease. METHODS: We incubated 3.2-mm punches from dried blood spots (DBS) for 22 h with the substrate [7-benzoylamino-heptyl)-{2-[4-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-phenylcarbamoyl]- ethyl}-carbamic acid tert-butyl ester] and internal standard [7-d(5)-benzoylamino-heptyl)-[2-(4-hydroxy-phenylcarbamoyl)-ethyl]-carbamic acid tertbutyl ester]. We quantified the resulting product and internal standard using MS/MS. We assessed inter- and intrarun imprecision, carryover, stability, and correlation between enzyme activities and hematocrit and punch location and generated a Pompe disease-specific cutoff value using routine newborn screening samples. RESULTS: GAA activities in DBS from 29 known Pompe patients were <2 micromol/h/L. GAA activities in routine newborn screening samples were [mean (SD)] 14.7 (7.2) micromol/h/L (n = 10,279, median 13.3, 95% CI 14.46-14.74 micromol/h/L) and in normal adult samples 9.3 (3.3) micromol/h/L (n = 229, median 9, 95% CI 8.88-9.72 micromol/h/L). GAA activity was stable for 28 days between 37 degrees C and -80 degrees C. Carryover could not be observed, whereas intrarun and interrun imprecision were <10%. The limit of detection was 0.26 micromol/h/L and limit of quantification 0.35 micromol/h/L. CONCLUSIONS: The measurement of GAA activities in dry blood spots using MS/MS is suitable for high-throughput analysis and newborn screening for Pompe disease.
Assuntos
Doença de Depósito de Glicogênio Tipo II/diagnóstico , Triagem Neonatal , Espectrometria de Massas em Tandem/métodos , alfa-Glucosidases/sangue , Adulto , Estudos de Casos e Controles , Doença de Depósito de Glicogênio Tipo II/enzimologia , Humanos , Recém-NascidoRESUMO
BACKGROUND: Reports of the use of multiplex enzyme assay screening for Pompe disease, Fabry disease, Gaucher disease, Niemann-Pick disease types A and B, and Krabbe disease have engendered interest in the use of this assay in newborn screening. We modified the assay for high-throughput use in screening laboratories. METHODS: We optimized enzyme reaction conditions and procedures for the assay, including the concentrations of substrate (S) and internal standard (IS), assay cocktail compositions, sample clean-up procedures, and mass spectrometer operation. The S and IS for each enzyme were premixed and bottled at an optimized molar ratio to simplify assay cocktail preparation. Using the new S:IS ratio, we validated the modified assay according to CLSI guidelines. Stability of the S, IS, and assay cocktails were investigated. Dried blood spots from 149 healthy adults, 100 newborns, and 60 patients with a lysosomal storage disorder (LSD) were tested using the modified assay. RESULTS: In our study, the median enzyme activity measured in adults was generally increased 2-3-fold compared to the original method, results indicating higher precision. In the multiplex format, each of the 5 modified enzyme assays enabled unambiguous differentiation between samples from healthy individuals (adults and newborns) and the corresponding disease-specific samples. CONCLUSIONS: The modified multiplex enzyme assay with premixed S and IS is appropriate for use in high-throughput screening laboratories.
Assuntos
Doenças por Armazenamento dos Lisossomos/diagnóstico , Espectrometria de Massas em Tandem/métodos , Adulto , Estudos de Casos e Controles , Humanos , Recém-Nascido , Doenças por Armazenamento dos Lisossomos/sangueRESUMO
Pompe's disease is caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). GAA is synthesized as a 110-kDa precursor containing N-linked carbohydrates modified with mannose 6-phosphate groups. Following trafficking to the lysosome, presumably via the mannose 6-phosphate receptor, the 110-kDa precursor undergoes a series of complex proteolytic and N-glycan processing events, yielding major species of 76 and 70 kDa. During a detailed characterization of human placental and recombinant human GAA, we found that the peptides released during proteolytic processing remained tightly associated with the major species. The 76-kDa form (amino acids (aa) 122-782) of GAA is associated with peptides of 3.9 kDa (aa 78-113) and 19.4 kDa (aa 792-952). The 70-kDa form (aa 204-782) contains the 3.9- and 19.4-kDa peptide species as well as a 10.3-kDa species (aa 122-199). A similar set of proteolytic fragments has been identified in hamster GAA, suggesting that the multicomponent character is a general phenomenon. Rabbit anti-peptide antibodies have been generated against sequences in the proteolytic fragments and used to demonstrate the time course of uptake and processing of the recombinant GAA precursor in Pompe's disease fibroblasts. The results indicate that the observed fragments are produced intracellularly in the lysosome and not as a result of nonspecific proteolysis during purification. These data demonstrate that the mature forms of GAA characterized by polypeptides of 76 or 70 kDa are in fact larger molecular mass multicomponent enzyme complexes.